viernes, 6 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 20, 2026

Prediction: The Best Pick-and-Shovel AI Stock of 2026 Won't Be Nvidia or Broadcom

View original at nasdaq.com
“TSMC anticipates its operating profit margin to be 57.5% in Q2 (at the midpoint of its guidance range).”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • TSMC forecasts 32% year-over-year revenue increase in Q2 2026 to $39.6 billion

    60% confidence
  • TSMC expects revenue to increase by more than 30% in 2026, revised from earlier forecast of close to 30%

    60% confidence
  • TSMC is expected to continue raising prices for its advanced chip nodes over the next four years

    60% confidence
  • Nvidia anticipates $1 trillion in AI data center chip sales in 2026 and 2027

    60% confidence
  • Broadcom sees $100 billion in AI chip revenue in fiscal 2027, up from $20 billion in fiscal 2025

    60% confidence
  • TSMC anticipates operating profit margin of 57.5% in Q2 2026 at the midpoint of guidance range

    60% confidence
  • TSMC could be the ultimate pick-and-shovel AI stock for 2026 and beyond due to its wider reach in AI chips than Nvidia and Broadcom

    60% confidence
  • Stock Advisor's total average return is 994%, outperforming the S&P 500's 199%

    60% confidence

Data points we hold from this source

Taiwan Semiconductor Manufacturing Company · forward earnings multiple25 ratio
Taiwan Semiconductor Manufacturing Company · net profit margin50.5 percent
Taiwan Semiconductor Manufacturing Company · eps3.49 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,996
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,996 hechos verificados con la fuente5,552 documentos fuente archivados
Consulta estos datos → isubstrate.com
Prediction: The Best Pick-and-Shovel AI Stock of 2026 Won't Be Nvidia or Broadcom — Source | Via News | es.VIA.NEWS